Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer - Concepedia

Concepedia

Publication | Open Access

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

DOI Full Paper Access

262

Citations

30

References

2009

Year

Daniel D. Karp, Luis Paz‐Ares, Silvia Novello, Paul Haluska, Linda L. Garland, Felipe Cardenal, L. Johnetta Blakely, Peter D. Eisenberg, Corey J. Langer, George R. Blumenschein,

Journal of Clinical Oncology

Abstract

These data suggest that PCI(20) is safe and effective in patients with NSCLC.

References

	Year	Citations

Page 1